Partnership Expansion Leverage recent collaboration with The London Clinic to position GALEAS tests as scalable non-invasive cancer diagnostics within NHS and private care networks, highlighting capabilities for bladder cancer and broader tumor profiling.

Clinical Adoption Target clinics and laboratories seeking integrated NGS workflows by offering GALEAS Tumor and GALEAS Hereditary Plus panels as end-to-end solutions that streamline genomic profiling, diagnosis, and personalized treatment planning.

Non-Invasive Focus Highlight GALEAS Bladder and liquid biopsy capabilities to reduce invasive procedures, lower patient burden, and improve diagnostic pathways, appealing to urology, oncology, and primary care partners.

Cloud Bioinformatics Promote the cloud-based GALEAS bioinformatics platform as a scalable, compliant solution for data analysis, reporting, and collaboration with clinical teams, appealing to labs expanding genomic testing capacity.

Global Growth Readiness Position Nonacus as a versatile partner for mid-market labs seeking growth through NGS panels and precision oncology workflows, leveraging ISO 9001 and existing Azure/Microsoft tech stack for easy integration.